# H101 Plus TACE for r/m HNSCC

Source: https://onco.cc/trials/nct07398664/  
OnCo record `nct07398664` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of H101 oncolytic adenovirus in Head and neck squamous cell carcinoma, run by West China Hospital, now recruiting.

## Summary

H101 Plus TACE for r/m HNSCC is a phase 2 interventional study registered as NCT07398664 by West China Hospital, with 20 participants planned, started 2026-03-02 and due to reach its primary completion in 2028-06-15. Interventions recorded: H101, TACE. Conditions recorded: Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE.

Linked to the drug H101 oncolytic adenovirus because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07398664
- Phase: 2
- Setting: Recombinant Human Adenovirus 5 (H101) Combined With Transcatheter Arterial Chemoembolization (TACE) for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Single-Center, Prospective Study
- Sponsor: West China Hospital
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07398664: https://clinicaltrials.gov/study/NCT07398664

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [H101 oncolytic adenovirus](https://onco.cc/drugs/h101-oncolytic-adenovirus/)

---
JSON: https://onco.cc/api/v1/entities/nct07398664.json